P
PFDeNA
Advanced AI solutions for cancer detection using deep learning and multi-business expertise
About PFDeNA
PFDeNA is a pioneering company that leverages advanced artificial intelligence (AI) and deep learning techniques to provide innovative business solutions and consumer services. The company operates in the healthcare sector, focusing on the early detection of cancer through sophisticated AI systems. By analyzing small amounts of blood, PFDeNA's technology can identify 14 different types of cancer, making it a valuable tool for early diagnosis and treatment.
PFDeNA serves a diverse range of clients, including healthcare providers, research institutions, and biotech companies. The company operates in the global healthcare market, where there is a growing demand for advanced diagnostic tools and personalized medicine. PFDeNA's business model revolves around offering AI-driven diagnostic solutions and consulting services, generating revenue through service fees, licensing agreements, and partnerships.
The company is a co-founder of the stock company Die en eevoe devorie and Preferred Networks (PFN), combining PFN's machine learning expertise with its own extensive experience in various business operations. This collaboration enhances PFDeNA's ability to deliver cutting-edge solutions that integrate AI, big data, and deep learning techniques.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sector
- Health, Hard Tech
- Technology
- Artificial Intelligence, Deep Learning
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | May 2020 | $3.1M | $12M | Undisclosed | — |
| LATE VCOther financing | Feb 2018 | $11M | $43M | Undisclosed | — |
Growth signals
Latest recorded traffic for PFDeNA is 620 monthly website visits, down 61.3% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 ElaitraAI-powered tomosynthesis imaging software for breast cancer detection |
London, United Kingdom | Operational | 4 | $673K | $422K |
 LaminOpen data platform for biology |
Munich, Germany | Operational | |||
 TrackPaw ScientificA platform aimed towards improving the current way of monitoring rodents used in preclinical research |
Lund Municipality, Sweden | Operational | |||
 e-pharmacyTransforming the future of healthcare by enabling any 3rd party to sell prescription medication directly to their customers |
Norwich, United Kingdom | Operational | |||
 Yatiri BioYatiri Bio – Beyond Genes |
San Diego, United States | Operational | |||
 CliniNoteEnables data-driven medicine |
Warsaw, Poland | Operational | |||
 DatapathologyMedical technology company focused on addressing delays in cancer diagnosis within Africa |
Dar-el-Beida, Morocco | Operational | |||
 Celeris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases |
Graz, Austria | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Source: Dealroom Talent Intelligence.
Market sentiment
An AI-synthesised read of the highest-engagement posts about PFDeNA on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PFDeNA’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.